Literature DB >> 26303038

Incidence of hip fracture in Brazil and the development of a FRAX model.

C A F Zerbini1, V L Szejnfeld, B H Abergaria, E V McCloskey, H Johansson, J A Kanis.   

Abstract

UNLABELLED: The Brazilian FRAX model is described and used to determine intervention thresholds for the treatment of osteoporosis.
INTRODUCTION: A FRAX model for Brazil was released May 1, 2013. This paper describes the data used to develop the Brazilian FRAX(®) model, illustrates its features and develops intervention thresholds.
METHODS: Age- and sex-stratified hip fracture incidence rates were extracted from four regional estimates from the age of 40 years. For other major fractures, Brazilian incidence rates were estimated using Swedish ratios for hip to other major osteoporotic fracture (humerus, forearm or clinical vertebral fractures). Assessment and intervention thresholds were determined using the approach recommended by the National Osteoporosis Guideline Group (UK) applied to the Brazilian FRAX model.
RESULTS: Fracture incidence rates increased with increasing age: for hip fracture, incidence rates were higher amongst younger men than women but with a female preponderance from the age of 50 years. Ten-year probability of hip or major fracture was increased in patients with a clinical risk factor, lower BMI, female gender, a higher age and a decreased BMD T-score. Of the clinical risk factors, prior fracture accounted for the greatest increase in 10-year fracture probability at younger ages while a parental hip fracture history was the strongest risk factor at ages 80-90 years. Age-dependent probability-based intervention thresholds were developed equivalent to women with a prior fragility fracture.
CONCLUSIONS: The FRAX tool is the first to provide a country-specific fracture prediction model for Brazil. It is based on the original FRAX methodology, which has been externally validated in several independent cohorts. Despite some limitations, the strengths make the Brazilian FRAX tool a good candidate for implementation into clinical practice.

Entities:  

Mesh:

Year:  2015        PMID: 26303038     DOI: 10.1007/s11657-015-0224-5

Source DB:  PubMed          Journal:  Arch Osteoporos            Impact factor:   2.617


  18 in total

1.  Unmasking romosozumab: response to commentsby Uzoigwe et al.

Authors:  F Cosman; D B Crittenden; C Libanati
Journal:  Osteoporos Int       Date:  2017-02-17       Impact factor: 4.507

2.  Incidence and risk factors for osteoporotic non-vertebral fracture in low-income community-dwelling elderly: a population-based prospective cohort study in Brazil. The São Paulo Ageing and Health (SPAH) study.

Authors:  D S Domiciano; L G Machado; C P Figueiredo; V F Caparbo; R M Oliveira; P R Menezes; R M R Pereira
Journal:  Osteoporos Int       Date:  2020-10-10       Impact factor: 4.507

Review 3.  Quality Improvement Initiatives in Fragility Fracture Care and Prevention.

Authors:  Paul J Mitchell; Cyrus Cooper; Masaki Fujita; Philippe Halbout; Kristina Åkesson; Matthew Costa; Karsten E Dreinhöfer; David R Marsh; Joon-Kiong Lee; Ding-Cheng Derrick Chan; M Kassim Javaid
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

4.  The incidence of hip fracture in Shiraz, Iran: a promising rate comparing to previous studies.

Authors:  N Maharlouei; S Atefi; H Namazi; S Kazemifar; M Soveid; H R Shahraki; Z Farahmand; M Khodayari; P Arab; F Forouzan; N Allamehzadeh; S Fazilat; S Khademolhosseini; F Nafari; K B Lankarani
Journal:  Osteoporos Int       Date:  2017-03-16       Impact factor: 4.507

5.  Secular trends in hip fractures in adults over 50 years old: a retrospective analysis of hospital admissions to the Brazilian Public Health System from 2004 to 2013.

Authors:  Alex Rocha Bernardes da Silva; Laura Christina Martinez; Marcelo de Medeiros Pinheiro; Vera Lúcia Szejnfeld
Journal:  Arch Osteoporos       Date:  2022-03-18       Impact factor: 2.617

6.  Romosozumab efficacy and safety in European patients enrolled in the FRAME trial.

Authors:  Bente Langdahl; Lorenz C Hofbauer; Serge Ferrari; Zhenxun Wang; Astrid Fahrleitner-Pammer; Evelien Gielen; Péter Lakatos; Edward Czerwinski; Esteban Jódar Gimeno; Jen Timoshanko; Mary Oates; Cesar Libanati
Journal:  Osteoporos Int       Date:  2022-09-29       Impact factor: 5.071

Review 7.  A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.

Authors:  John A Kanis; Nicholas C Harvey; Cyrus Cooper; Helena Johansson; Anders Odén; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2016-07-27       Impact factor: 2.617

Review 8.  A brief history of FRAX.

Authors:  John A Kanis; Helena Johansson; Nicholas C Harvey; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2018-10-31       Impact factor: 2.617

Review 9.  Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.

Authors:  N C W Harvey; E V McCloskey; P J Mitchell; B Dawson-Hughes; D D Pierroz; J-Y Reginster; R Rizzoli; C Cooper; J A Kanis
Journal:  Osteoporos Int       Date:  2017-02-07       Impact factor: 4.507

Review 10.  Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumatology (2020).

Authors:  Rosa M R Pereira; Mariana O Perez; Ana Patrícia Paula; Caio Moreira; Charlles H M Castro; Cristiano A F Zerbini; Diogo S Domiciano; Elaine de Azevedo; Laura M C Mendonca; Marcia Midore Shinzato; Marco Antonio A da Rocha-Loures; Sebastião Radominski; Vera L Szejnfeld
Journal:  Arch Osteoporos       Date:  2021-03-01       Impact factor: 2.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.